Anavex life sciences announces participation at upcoming world epa - evidence, pricing and access - congress 2021

New york, april 07, 2021 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) diseases, today announced that its president and chief executive officer, christopher u. missling, phd, will join a panel discussion titled, “establishing mutually beneficial collaborations,” at the world epa congress 2021 event on thursday, april 15t h at 8:55 a.m. edt (14:55 cet).
AVXL Ratings Summary
AVXL Quant Ranking